Search

Your search keyword '"Flisiak, R."' showing total 781 results

Search Constraints

Start Over You searched for: Author "Flisiak, R." Remove constraint Author: "Flisiak, R."
781 results on '"Flisiak, R."'

Search Results

1. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

2. Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study

3. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

4. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

5. A global research priority agenda to advance public health responses to fatty liver disease

6. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

8. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

9. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

10. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

11. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

12. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

13. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

16. Advancing the global public health agenda for NAFLD: a consensus statement

17. Observational cohort study of rilpivirine (RPV) utilization in Europe

19. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

20. Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference

21. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

22. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

23. Predictors of clinical response: results from a large, randomized controlled study with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)

25. The present and future disease burden of hepatitis C virus (HCV) infections with todayʼs treatment paradigm – volume 2

26. Strategies to manage hepatitis C virus (HCV) infection disease burden – volume 2

27. Historical epidemiology of hepatitis C virus (HCV) in select countries – volume 2

28. The case for simplifying and using absolute targets for viral hepatitis elimination goals

29. The case for simplifying and using absolute targets for viral hepatitis elimination goals.

30. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens

32. Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment-naive patients with HCV genotype 1: phase 3 COMMAND-3 results: O213

33. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

34. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection

35. Long‐term effectiveness of recommended boosted protease inhibitor‐based antiretroviral therapy in Europe

38. Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy

40. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

41. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

42. Correction to: Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis (Digestive Diseases and Sciences, (2018), 63, 12, (3487-3497), 10.1007/s10620-018-5251-9)

43. Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.

44. Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe

45. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

46. Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort

48. Real life results of direct acting antiviral therapy for HCV infection in HIV–HCV-coinfected patients: Epi-Ter2 study

49. Liver-related death among HIV/hepatitis C virus-co-infected individuals

50. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study.

Catalog

Books, media, physical & digital resources